Abcellera Biologics Inc ABCL

$9.86 -0.61 (-5.83%)

Valuation

Market cap
3,599,331,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,040,721
Avg volume
4,265,644
Day's range
$9.82 – $10.26
Shares out
326,618,000
Stochastic %K
3%
Beta
1.59
Analysts
Strong Buy
Price target
$18.61

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

StocksReportsX Nov 20, 6:01 PM
I didn’t write off $IVDA, brother. I was pointing out how rough the broader market is and mentioned $IVDA and $ABCL in that context. I agree with you about Iveda’s potential; I’m just making sure we’re considering the market conditions around it too.
0 replies
flymetothemoon2 Nov 20, 5:54 PM 0 replies
StocksReportsX Nov 20, 5:45 PM
$NVDA -7.3%, $AMD -11.4%, $MU -12.5% on this heatmap. Meanwhile, Walmart, Costco, and P&G are green. Apparently, groceries and toothpaste look more appealing than AI today. Defensive rotation or the start of a deeper reset? $IVDA -6.90% $ABCL -5.92%
0 replies
flymetothemoon2 Nov 20, 5:37 PM 0 replies
StocksReportsX Nov 20, 5:31 PM 0 replies
Odoji Nov 20, 5:13 PM
$ABCL 💉💉
0 replies
flymetothemoon2 Nov 20, 5:12 PM 0 replies
ITF Nov 20, 5:05 PM
$ABCL VIX over 30 Fear and greed - at extreme Capitulation peak? Buy buy buy
0 replies